Laddar...
Study design and rationale of "Synergistic Effect of Combination Therapy with Cilostazol and ProbUcol on Plaque Stabilization and Lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial
BACKGROUND: Probucol, a cholesterol-lowering agent that paradoxically also lowers high-density lipoprotein cholesterol has been shown to prevent progression of atherosclerosis. The antiplatelet agent cilostazol, which has diverse antiatherogenic properties, has also been shown to reduce restenosis i...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2011
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3033833/ https://ncbi.nlm.nih.gov/pubmed/21226953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-12-10 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|